Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 11, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 15, 2025
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001682852-25-000094
Filed / recorded
Dec 15, 2025, 1:59 PM UTC
Added to OQRO
Oct 2, 2026, 12:28 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
Moderna, Inc.
Issuer CIK
1682852
Ticker
MRNA
Reporting person
Stephane Bancel
Relationship
Director, Officer
Officer title
Chief Executive Officer
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Dec 11, 2025
Transaction code
M
Shares / units
688,073
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Direct
Amendment
No
Footnotes from the filing
The Reporting Person acquired 688,073 shares of the Issuer's common stock upon the exercise in full of a stock option scheduled to expire on February 23, 2026. The option would have been forfeited if not exercised prior to that date. The Reporting Person paid the full exercise price of $7,499,995.70 ($10.90 per share) and applicable withholding taxes of $5,998,279.76 in cash, for a total cash amount of $13,498,275.46. No shares of the Issuer were sold or withheld in connection with the exercise.